Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Rob Riemsma"'
Autor:
Nigel Armstrong, Nasuh Büyükkaramikli, Hannah Penton, Rob Riemsma, Pim Wetzelaer, Vanesa Huertas Carrera, Stephanie Swift, Thea Drachen, Heike Raatz, Steve Ryder, Dhwani Shah, Titas Buksnys, Gill Worthy, Steven Duffy, Maiwenn Al, Jos Kleijnen
Publikováno v:
Health Technology Assessment, Vol 24, Iss 51 (2020)
Background: There have been no licensed treatment options in the UK for treating thrombocytopenia in people with chronic liver disease requiring surgery. Established management largely involves platelet transfusion prior to the procedure or as rescue
Externí odkaz:
https://doaj.org/article/c59e5b6200d84298a2c9f75acd4ef74a
Autor:
Rob Riemsma, Isaac Corro Ramos, Richard Birnie, Nasuh Büyükkaramikli, Nigel Armstrong, Steve Ryder, Steven Duffy, Gill Worthy, Maiwenn Al, Johan Severens, Jos Kleijnen
Publikováno v:
Health Technology Assessment, Vol 20, Iss 17 (2016)
Background: In recent years, meters for continuous monitoring of interstitial fluid glucose have been introduced to help people with type 1 diabetes mellitus (T1DM) to achieve better control of their disease. Objective: The objective of this project
Externí odkaz:
https://doaj.org/article/cef3222f3338437f8d6576a53d7d4d0a
Autor:
Nigel Armstrong, Laura Burgers, Sohan Deshpande, Maiwenn Al, Rob Riemsma, SR Vallabhaneni, Peter Holt, Johan Severens, Jos Kleijnen
Publikováno v:
Health Technology Assessment, Vol 18, Iss 70 (2014)
Background: Patients with large abdominal aortic aneurysms (AAAs) are usually offered reparative treatment given the high mortality risk. There is uncertainty about how to treat juxtarenal AAAs (JRAAAs) or thoracoabdominal aortic aneurysms (TAAAs). E
Externí odkaz:
https://doaj.org/article/ab8afe61e0154ce38d5b6a81b3b2db4d
Autor:
Thomas Otten, Rob Riemsma, Ben Wijnen, Nigel Armstrong, Lisa Stirk, Caroline Gordon, Bram Ramaekers, Jos Kleijnen, Manuela Joore, Sabine Grimm
Publikováno v:
Pharmacoeconomics. 40(9):851-861
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (GlaxoSmithKline [GSK]) of Benlysta (belimumab) to submit evidence regarding its clinical and cost effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae7ebe108ef0e5c063abec382b37344
https://doi.org/10.1007/s40273-022-01166-2
https://doi.org/10.1007/s40273-022-01166-2
Autor:
Rob Riemsma, Debra Fayter, Lloyd Brandts, John R. Kirwan, Kate Misso, Ben F. M. Wijnen, Nigel Armstrong, Jos Kleijnen, Charlotte Ahmadu, Sabine Grimm, Manuela A. Joore
Publikováno v:
Pharmacoeconomics
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Gilead) of filgotinib (Jyseleca(TM)), as part of the single technology appraisal process, to submit evidence for its clinical and cost effectiveness for the treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bc99d56d37bc3c1a3384803a728dfa
https://doi.org/10.1007/s40273-021-01080-z
https://doi.org/10.1007/s40273-021-01080-z
Autor:
Manuela A. Joore, Jos Kleijnen, Alastair K Denniston, Svenja Petersohn, Vanesa Huertas Carrera, Gill Worthy, Annette Chalker, Willem J.A. Witlox, Caro Noake, Nigel Armstrong, Xavier Pouwels, Heike Raatz, Rob Riemsma
Publikováno v:
Pharmacoeconomics, 38(6), 649-651. Adis International Ltd
PharmacoEconomics, 38, 649-651. Adis International Ltd
PharmacoEconomics, 38, 649-651. Adis International Ltd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b5e87c9dc8dabcd80a101a522aa1ad1
https://doi.org/10.1007/s40273-020-00900-y
https://doi.org/10.1007/s40273-020-00900-y
Autor:
Vanesa Huertas Carrera, Svenja Petersohn, Gill Worthy, Heike Raatz, Alastair K Denniston, Annette Chalker, Manuela A. Joore, Xavier Pouwels, Rob Riemsma, Caro Noake, Nigel Armstrong, Jos Kleijnen, Willem J.A. Witlox, Dhwani Shah
Publikováno v:
Pharmacoeconomics
The National Institute for Health and Care Excellence (NICE) invited Alimera Sciences, the company manufacturing fluocinolone acetonide intravitreal implant (FAc) 0.19 mg (tradename ILUVIEN), to submit evidence on the clinical and cost-effectiveness
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c28282025c9a856b1360e9c0e2ca650
https://doi.org/10.1007/s40273-019-00851-z
https://doi.org/10.1007/s40273-019-00851-z
Autor:
Debra Fayter, Nasuh Büyükkaramikli, Kate Misso, Frederick W. Thielen, Ching-Yun Wei, Gill Worthy, Isaac Corro Ramos, Rob Riemsma, Nigel Armstrong, Jos Kleijnen, Vanesa Huertas Carrera
Publikováno v:
Pharmacoeconomics. 37(8):975-984
The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the company that makes obinutuzumab (Roche Products Limited) to submit evidence of the clinical and cost eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::364c385c546ead15c90023eeb384b81b
https://doi.org/10.1007/s40273-018-0740-4
https://doi.org/10.1007/s40273-018-0740-4
Autor:
Jos Kleijnen, Nigel Armstrong, Gill Worthy, Bram Ramaekers, Debra Fayter, Sohan Deshpande, Xavier Pouwels, Rob Riemsma, Steven Duffy, Manuela A. Joore, Sabine Grimm, Willem J.A. Witlox
Publikováno v:
Pharmacoeconomics
The National Institute for Health and Care Excellence (NICE) invited Teva, the company manufacturing arsenic trioxide (ATO; tradename Trisenox((R))), to submit evidence for the clinical and cost effectiveness of ATO for untreated and relapsed or refr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6c2e99542624f0f4b6c7e351e630e0b
https://doi.org/10.1007/s40273-018-0738-y
https://doi.org/10.1007/s40273-018-0738-y
Autor:
Maiwenn Al, Jos Kleijnen, Steven Duffy, Saskia de Groot, Nigel Armstrong, Debra Fayter, Nasuh Büyükkaramikli, Rob Riemsma, Piet J. M. Portegijs
Publikováno v:
Pharmacoeconomics (Print). Adis
Pharmacoeconomics
Pharmacoeconomics
The National Institute for Health and Care Excellence, as part of the institute's single technology appraisal process, invited the manufacturer of ribociclib (Kisqali((R)), Novartis) to submit evidence regarding the clinical and cost effectiveness of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae545490e0f8cffa8a41d47a59246ca
https://doi.org/10.1007/s40273-018-0708-4
https://doi.org/10.1007/s40273-018-0708-4